MedChemExpress LLC notes that Utrophin is being explored as a potential substitute for dystrophin, including CRISPR/Cas9-based approaches to boost its expression.
Public source
Publisher name
Public post
🧬Rare Disease Focus | #DMD Rare doesn’t mean insignificant. September 7 marks World Duchenne Awareness Day, with this year’s theme, “Access Changes Lives.” Duchenne mus…
Company
MedChemExpress LLC
Master of Bioactive Molecules.
- Industry
- Biotechnology Research
- Location
- Monmouth Junction, US
- Company size
- 51–200 employees
About MedChemExpress LLC
MedChemExpress (MCE) is a leading global supplier of life science reagents, dedicated to providing innovative solutions for scientific research and drug development. We offer a comprehensive range of high-quality active molecules, including inhibitors, compound libraries, recombinant proteins, antibodies, and more, positioning itself as a leading global supplier of research chemicals and bioactive compounds. Headquartered in New Jersey, USA, MCE has established multiple R&D, production, and logistics centers worldwide. With a team of seasoned experts, MCE has built an end-to-end service system, encompassing services such as HNMR data analysis, bioactivity evaluation, technical consultation, and after-sales support. Backed by stringent management systems and quality control standards, MCE delivers efficient, precise, and reliable services to over 15,000 research institutions worldwide. Committed to driving innovation in drug discovery, MCE is your trusted long-term partner for scientific exploration and pharmaceutical research. https://linktr.ee/MedChemExpress
See moreLatest activity
Latest activity from MedChemExpress LLC
14 signals
Research & Knowledge
MedChemExpress LLC reported that in a Phase 3 trial, Avexitide reduced the composite rate of Level 2 and Level 3 hypoglycemic events by 55% vs. placebo in 78 participants, meeting all secondary endpoints.
Research & Knowledge
MedChemExpress LLC published an article tracing the molecular cascade driven by Aβ from production and aggregation to neuronal and synaptic dysfunction.
Research & Knowledge
MedChemExpress LLC published a study finding that mutant KRAS can reshape the tumor microbiome and enrich Bacteroides acidifaciens.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Precision BioSciences, Inc.
Precision BioSciences, Inc. reported that the first participant in the FUNCTION-DMD clinical trial received an investigational gene-editing treatment, PBGENE-DMD, designed to permanently address the underlying cause of Duchenne muscular dystrophy.
Research & Knowledge
ScienTek
ScienTek STV-C8 successfully delivered CRISPR/Cas9 components for gene editing in pig muscle, removing a section of the dystrophin gene.
Research & Knowledge
Biochrom Ltd.
Biochrom Ltd. published a new protocol for generating endothelial cell-specific knockout mice using CRISPR/Cas9 in STAR Protocols, reporting 84–90% editing efficiency and quantification using the BioDrop microvolume spectrophotometer.
Research & Knowledge
HitChem
HitChem published a new study in Nature Communications suggesting that a surprisingly small chemical edit may be enough to degrade KRAS.
Research & Knowledge
Prime Medicine, Inc.